Loss narrows sharply. Lexicon Pharmaceuticals reported a loss of $0.04 per share for Q4 2025, narrowing 55.6% from the $0.09 per share loss in the year-ago quarter. The biotechnology company posted a net loss of $15.5 million for the quarter, with operating losses of $14.8 million partially offset by gross profit of $5.3 million.
Revenue collapses year-over-year. Q4 revenue totaled $5.5 million, down 79.3% from the prior-year quarter. Cost of revenue remained minimal at $201 million, suggesting the company maintained strong gross margins despite the sharp revenue decline. The stock traded flat at $1.61 following the release, with volume of 2.4 million shares.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.